3B Blackbio Dx growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY25Mar 2025
+28.0%
+42.0%
+43.1%
+39.0%
+18.9%
+19.8%
+56.2%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), standalone. For information only, not investment advice.

3BBLACKBIO₹1,359.20

3B Blackbio Dx Limited

· Pharma & Health
₹ CrorePeersHEALTHXSURAKSHAKRSNAANEPHROPLUS
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
Revenue Growth—+28.0
EBITDA Growth—+42.0
EBIT Growth—+43.1
Net Income Growth—+39.0
Total Assets Growth—+18.9
Total Equity Growth—+19.8
Cash from Operations Growth—+56.2
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · StandaloneFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.